Almac Discovery received approval to initiate its Phase I dose escalation study to investigate subcutaneous ALM201 in advanced ovarian cancer and other solid tumors. The company began dosing the first patient with ALM201, a therapeutic peptide derived from FKBPL, a natural protein that binds CD44. ALM201 has multiple modes of action including anti-angiogenesis, a mechanism that is particularly relevant in ovarian cancer.   Epithelial ovarian cancer (EOC) is among the top ten diagnosed cancers, w...